Esophageal cancer-related gene 4 protein (ECRG4)

Esophageal cancer-related gene 4 protein (ECRG4), also known as Augurin and encoded by the C2orf40 gene, is a highly conserved, hormone-like peptide precursor broadly expressed in epithelial, neural, cardiovascular, and immune tissues[3][4][5]. ECRG4 is processed into multiple bioactive peptides that can remain tethered to cell membranes or be released into the extracellular space[3][1]. ECRG4 acts as a tumor suppressor, with most cancers showing its downregulation via promoter methylation or loss of expression, correlating with increased malignancy and poorer prognosis[2][3][4][6]. ECRG4 modulates inflammation by interacting with scavenger receptors (such as LOX-1, Scarf1, CD36, Stabilin-1) and the TLR4/CD14/MD2 immune receptor complex, leading to NF-κB activation and cytokine/chemokine production in macrophages and microglia[1][3]. It also negatively regulates cell proliferation (often via cell cycle arrest and apoptosis induction), Wnt signaling, and has been proposed as a sentinel protein orchestrating tissue homeostasis and injury responses in the CNS, cardiovascular system, and other tissues[3][2][4][5]. There are currently no known approved drugs targeting ECRG4 directly, but its loss or decreased expression has utility as a prognostic biomarker, and its biology suggests therapeutic promise in cancer and possibly in cardiovascular or inflammatory diseases[2][3][4][6].

Other names

AugurinC2orf40UNQ761/PRO1508esophageal cancer-related gene 4 proteinaugurin precursorECRG4 augurin precursorECRG4

Not applicable or unknown (no approved drugs; ECRG4 modulates multiple signaling pathways, such as PI3K/Akt/mTOR and Wnt, and interacts with scavenger receptors and TLR4 immune complexes)[1][3]